NCT06665555View on ClinicalTrials.gov

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

March 13, 2025

Study Completion Date

March 17, 2025

Conditions
PharmacokineticsHealthy Volunteers
Interventions
DRUG

ledaborbactam etzadroxil

Five doses of ledaborbactam etzadroxil will be administered orally every 12 hours

DRUG

ceftibuten

Five doses of ceftibuten will be administered orally every 12 hours

Trial Locations (1)

85032

Pulmonary Associates, Phoenix

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Venatorx Pharmaceuticals, Inc.

INDUSTRY

NCT06665555 - Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age | Biotech Hunter | Biotech Hunter